My Opinion of Highest ROI Peptides, by Nevin Pratt

BPC-157

Soft tissue injury repair.  Half life 6-8 hrs.  Local injection at an injury site is best, but systemic (in the stomache area) works quite well too. People often mix this with TB-500 in the same vial, but I recommend against that.  Those two peptides have a different PH and a different half life.  Keep them separate.

Dosage: 300mcg to 600mcg daily.  
5mg vial with 2cc BAC = 20 units daily = 500mcg/dose.
10mg vial with 2cc BAC = 10 units daily = 500mcg/dose.
10mg vial with 3cc BAC = 10 units for 333mcg.

A study on using BPC-157 for regeneration can be found here.

Here are a couple of Youtube short videos on it.  The first is a Joe Rogan interview, and the second is from a well-known Stanford University professor, Dr. Andrew Huberman:

https://www.youtube.com/shorts/EVejn72GgQo
https://www.youtube.com/shorts/kOUvJVD_78U

Dr. Trevor Bachmeyer calls it a "forever peptide", to be taken daily, and talks extensively about BPC-157 in this video:

https://youtu.be/nRi9GqTfGqY?si=bh2tuRTmX64_awQW

I recommend every other day for BPC-157, and every other day for TB-500.  If your kangaroo doesn't like that many shots, combining them into the same syringe at the time of injection is the next best thing.

If your kangaroo can tolerate daily injections, then inject BPC-157 daily, and TB-500 every other day.

KPV

Skin health, psoriasis, eczema.  Wound healing (a bit like BPC-157).  Reduces inflamation.

Dosage: 200-500mcg daily. 10mg vial with 2.5cc BAC, 10 units = 400mcg.

MOTS-C

"Exercise in a bottle"-- it's an exercise mimetic peptide.  Anti-aging.  Bone health.  MOTS-C is an AMPK upregulator, which boosts glucose uptake.  In other words, it tells your cells "it's daytime".  It also delays melatonin release.  This means it can keep you awake, and give you energy.  Only take this in the morning.  Taking it late in the day can lead to insomnia.

Dosage: 0.5-1mg 3-5x per week., or 2.5-5mg 1-2x per week. 
10mg vial with 2cc BAC = 1mg per 20 units. 

Retatrutide

Retatrutide (reta) is currently (Nov 2025) in Phase 3 human trials.  Phase 2 trial results were published last month in the New England Journal of Medicine.  Here is a link to the phase 2, double-blind, randomized, placebo-controlled trial:

https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

300mcg to 600mcg daily.  16mg vial with 1.6cc BAC = 1mg per 10 units. 16mg vial with 3.2cc BAC = 500mcg per 10 units.

Weight Loss: Results are substantially better than with semaglutide (Ozempic) or tirzepatide (Monjauro). At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of reta; 100%, 91%, and 75% of those who received 8 mg. The most common adverse events in the reta groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.

Other Benefits: Treatment with reta was associated with improvements in cardiometabolic measures (exploratory end points) including systolic and diastolic blood pressure and levels of glycated hemoglobin, fasting glucose, insulin, and lipids (with the exception of high-density lipoprotein [HDL] cholesterol).

Endorsements: A very interesting endorsement is this one by Dr. Trevor Bachmeyer.  He states that in his opinion the weight loss aspects of reta are the least important of the benefits, and he gives compelling reasons for that in this video:

https://youtu.be/3Xjn3aIHi3Y?si=Zo5Dl7kCdtVYevCI

He says that in his opinion semaglutide (Ozempic) and tirzepatide (Monjauro) are trash and should be thrown away, and reta used instead.

TB-500

Soft tissue injury repair.  Systemic injection.

Dosage: 300mcg to 1mg daily.
5mg vial with 2cc BAC = 20 units daily = 500mcg per dose.
10mg vial with 1.5cc BAC = 15 units per mg.
10mg vial with 3cc BAC = 10 units for 333mcg